Citigroup Maintains Neutral on Quest Diagnostics, Raises Price Target to $145
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Patrick Donnelly has maintained a Neutral rating on Quest Diagnostics (NYSE:DGX) and increased the price target from $130 to $145. This adjustment reflects Citigroup's updated valuation of the company's stock.

December 11, 2023 | 12:12 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Citigroup analyst Patrick Donnelly has reaffirmed a Neutral rating on Quest Diagnostics and raised the price target to $145, indicating a potential upside from the previous target of $130.
The increase in price target by Citigroup suggests a positive outlook on the stock's value, which could lead to short-term price appreciation. However, the Neutral rating implies that the analyst does not see significant momentum beyond the revised target, tempering the potential impact.
CONFIDENCE 90
IMPORTANCE 60
RELEVANCE 100